Veeva Pulse Field Trends Report
As the pharmaceutical industry continues to adapt to HCP preferences and hybrid commercial models, it’s critical to stay on top of evolving field and HCP engagement trends.
Each quarter, the Veeva Pulse Field Trends Report provides unique insights into global and regional engagement trends based on analysis of 600 million HCP interactions across more than 80% of biopharmas worldwide.See the Insights
Field Medical Has a Significant Impact on Launch Success
For the first time, the biopharma industry has clear data demonstrating the impact of field medical on clinical practice in a launch setting.
Medical science liaison (MSL) engagement with key opinion leaders (KOLs) before product launch, either in person or via video, results in 1.5 times greater treatment adoption across the healthcare organization (HCO) within the first six months of launch, compared to HCOs whose KOLs were not engaged.
This early education by MSLs has a lasting impact, as new treatment starts sustain at 1.3 times greater 18 to 24 months after product launch.
Despite Demand, 70% of KOLs Engage with Only One Biopharma
While the depth of individual connections between MSLs and KOLs may be substantial, the breadth of engagement is not. New Veeva Pulse and Veeva Link data shows that nearly 70% of KOLs only interact with one company’s field medical team.
Identify and Prioritize High-Impact KOLs With Industry Data
Real-time, connected data can broaden access to the right scientific experts as well generate and share insights across the organization quickly and effectively.
By using a data-driven approach, MSLs at one top pharma company improved scientific engagement strategy with medical experts: